The estimated Net Worth of Edward Stelmakh is at least 155 千$ dollars as of 3 October 2023. Mr Stelmakh owns over 16,662 units of OptimizeRx Corp stock worth over 155,384$ and over the last 2001 years he sold OPRX stock worth over 0$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr MBA OPRX stock SEC Form 4 insiders trading
Mr has made over 4 trades of the OptimizeRx Corp stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 16,662 units of OPRX stock worth 121,299$ on 3 October 2023.
The largest trade he's ever made was exercising 16,662 units of OptimizeRx Corp stock on 3 October 2023 worth over 121,299$. On average, Mr trades about 5,282 units every 52 days since 23. As of 3 October 2023 he still owns at least 21,344 units of OptimizeRx Corp stock.
You can see the complete history of Mr Stelmakh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Edward Stelmakh C.M.A., M.B.A., MBA biography
Edward Stelmakh C.M.A., M.B.A., MBA is the CFO & COO at OptimizeRx Corp.
What's Mr MBA's mailing address?
Edward's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.
Insiders trading at OptimizeRx Corp
Over the last 2001 years, insiders at OptimizeRx Corp have traded over 20,012,815$ worth of OptimizeRx Corp stock and bought 258,753 units worth 1,128,145$ . The most active insiders traders include Investment Company, Inc. Awm、Bradley Louis Radoff、David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of 183,485$. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth 73,244$.
What does OptimizeRx Corp do?
optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.
What does OptimizeRx Corp's logo look like?
Complete history of Mr Stelmakh stock trades at OptimizeRx Corp
OptimizeRx Corp executives and stock owners
OptimizeRx Corp executives and other stock owners filed with the SEC include:
-
Stephen Silvestro,
Chief Commercial Officer -
William Febbo,
Chief Executive Officer, Director -
William J. Febbo,
CEO & Director -
Stephen L. Silvestro,
Chief Commercial Officer -
Miriam Paramore,
President -
Douglas Baker,
Chief Financial Officer -
Gus Halas,
Chairman of the Board -
Lynn Vos,
Independent Director -
Patrick Spangler,
Independent Director -
James Lang,
Independent Director -
Angelo Campano,
Senior Vice President - Principal of Agency Channels -
Ron Both,
Investor Relations -
Gregory Wasson,
Director -
Todd Inman,
Chief Technology Officer -
Maira Alejandra,
Media Relations Mang. -
Todd Inman,
Chief Technology Officer -
Andrew Jacob D'Silva,
Sr. VP of Corp. Fin. -
Douglas P. Baker,
Exec. VP of Fin. & Accounting -
Edward Stelmakh C.M.A., M.B.A., MBA,
CFO & COO -
Rebecca Whitney,
Sr. VP of Commercial Operations -
Terence J. Hamilton,
Sr. VP of Pharma -
Sheryl Kearney,
HR Mang. -
Marion K Odence-Ford,
Gen. Counsel & Chief Compliance Officer -
Cathy Klema,
Director -
Ellen O'connor Vos,
Director -
Plc Wpp Luxembourg Gamma Th...,
-
Investment Company, Inc. Awm,
10% owner -
Bradley Louis Radoff,
10% owner -
Jack T Pinney,
Director -
Richard Kraniak,
10% owner -
David Lester,
Chairman of the Board -
David Harrell,
Chief Executive Officer -
Terrence Hamilton,
Vice President -
James M Brooks,
SVP of Business Development -
Brian J Dillon,
SR. VP OF PRODUCT & STRATEGY -
Brian Clark Mc Carthy,
Chief Revenue Officer -
Marion Odence Ford,
General Counsel and CCO -
Edward Stelmakh,
CFO/COO -
Doug Besch,
Chief Product Officer -
Theresa Greco,
Chief Commercial Officer